{"nctId":"NCT01321541","briefTitle":"Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant","startDateStruct":{"date":"2011-04-20","type":"ACTUAL"},"conditions":["Diffuse Large B-cell Lymphoma","de Novo DLBCL","DLBCL Transformed From Indolent Lymphoma","Follicular Grade 3 Lymphoma"],"count":312,"armGroups":[{"label":"Pixantrone + Rituximab","type":"EXPERIMENTAL","interventionNames":["Drug: Pixantrone + Rituximab"]},{"label":"Gemcitabine + Rituximab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Gemcitabine + Rituximab"]}],"interventions":[{"name":"Pixantrone + Rituximab","otherNames":[]},{"name":"Gemcitabine + Rituximab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Diagnosis of DLBCL (de novo DLBCL, or transformed from indolent lymphoma) or follicular grade 3 lymphoma on the basis of tissue biopsy.\n2. Patients with de novo DLBCL must have received 1-3 treatment regimens for DLBCL. Patients with follicular grade 3 lymphoma must have received 1-3 treatment regimens for follicular lymphoma (any grade). Patients with DLBCL transformed from indolent lymphoma must have received at least 1-4 treatment regimens for NHL.\n3. Received rituximab containing a multi-agent therapy for the treatment of NHL.\n4. Not eligible for high-dose chemotherapy and stem cell transplant.\n5. Patients with DLBCL transformed from indolent lymphoma must have had a complete or partial response to a therapy for NHL lasting at least 12 weeks.\n\nExclusion Criteria:\n\n1. Primary refractory de novo DLBCL or primary refractory follicular grade 3 lymphoma, defined as documented progression within 12 weeks of the last cycle of the first-line multi-agent regimen.\n2. Prior treatment with cumulative dose of doxorubicin or equivalent exceeding 450 mg/m2\n3. Any experimental therapy â‰¤ 28 days prior to randomization\n4. Other malignancy within last 5 years except for the following: curatively treated basal cell/squamous cell skin cancer, carcinoma in situ of the cervix, superficial transitional cell bladder carcinoma, or in situ ductal carcinoma of the breast after complete resection\n5. Any contraindication or known allergy or hypersensitivity to any study drugs\n6. Concomitant therapy with any anticancer agents, immunosuppressive agents, other investigational anticancer therapies. Low-dose corticosteroids for the treatment of non cancer-related illnesses are permitted.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS)","description":"PFS is defined as the time of randomization to the date of disease progression or death due to any cause (whichever occurs first)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival is from randomization to death due to any cause","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":null},{"groupId":"OG001","value":"19.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response Rate","description":"CRR is defined as the proportion of patients who achieve a Complete Response (CR) without additional therapy. CR is defined as the disappearance of all target lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate","description":"ORR is defined as the proportion of patients who achieve a CR or PR without additional therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.9","spread":null},{"groupId":"OG001","value":"43.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Adverse Events (TEAE) Related to Study Drug","description":"The number of Participants with Treatment Emergent Adverse Events (TEAE) related to study drug (pixantrone or gemcitabine)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"140","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Individual Concentration-time Profiles of Patients Will be Compared to Existing Data Using Simulations (Visual Predictive Checks)","description":"To characterize the PK profile of pixantrone when co-administered with rituximab. Plasma samples for PK analysis will be collected relative to the D-1 dose of pixantrone in one of the 6 treatment cycles for each participating patient. The goal is to enroll approx. 20 patients, active at 20 sites- Beatson West of Scotland Cancer Center, Uni. Hospital Kralovske Vinohrady, Uni. Hospital Hradec Kralove Hematooncology, Hospital Nuernberg, St. Marien Hospital Hamm, Puerta del Mar Hospital, Tokuda Hospital Sofia, National Center of Hematology \\& Transfusiology, UMHAT \"SV. IVAN RILSKI\", Moritz Kaposi General Hospital, Uni. of Debrecen, Polish Red Cross Marine Hospital, Kharkiv Regional Clinical Oncology Center, National Inst. of Cancer Ukraine, Cherkasy Regional Oncology Center, Inst. of Blood Pathology \\& Transfusion Medicine, Uni. Hospital Martin, National Onclogy Inst., Uni. Hospital with Outpatient Clinic F.D. Roosevelt Banska Bystrica, Uni. Hospital J.A. Reiman Presov","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"To Generate Individual Secondary PK Parameters (eg, Exposure, Half-life Etc.) Using Descriptive Statistics","description":"To characterize the PK profile of pixantrone when co-administered with rituximab. Plasma samples for PK analysis will be collected relative to the D-1 dose of pixantrone in one of the 6 treatment cycles for each participating patient. The goal is to enroll approx. 20 patients, active at 20 sites- Beatson West of Scotland Cancer Center, Uni. Hospital Kralovske Vinohrady, Uni. Hospital Hradec Kralove Hematooncology, Hospital Nuernberg, St. Marien Hospital Hamm, Puerta del Mar Hospital, Tokuda Hospital Sofia, National Center of Hematology \\& Transfusiology, UMHAT \"SV. IVAN RILSKI\", Moritz Kaposi General Hospital, Uni. of Debrecen, Polish Red Cross Marine Hospital, Kharkiv Regional Clinical Oncology Center, National Inst. of Cancer Ukraine, Cherkasy Regional Oncology Center, Inst. of Blood Pathology \\& Transfusion Medicine, Uni. Hospital Martin, National Onclogy Inst., Uni. Hospital with Outpatient Clinic F.D. Roosevelt Banska Bystrica, Uni. Hospital J.A. Reiman Presov","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":59,"n":153},"commonTop":["Neutropenia","Thrombocytopenia","Anaemia","Fatigue","Nausea"]}}}